<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Renalytix Plc — News on 6ix</title>
<link>https://6ix.com/company/renalytix-plc</link>
<description>Latest news and press releases for Renalytix Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/renalytix-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d58691beedb30cb6f8c0f0.webp</url>
<title>Renalytix Plc</title>
<link>https://6ix.com/company/renalytix-plc</link>
</image>
<item>
<title>Key milestones achieved for kidneyintelX.dkd</title>
<link>https://6ix.com/company/renalytix-plc/news/key-milestones-achieved-for-kidneyintelxdkd</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/key-milestones-achieved-for-kidneyintelxdkd</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>Renalytix plc has achieved key regulatory milestones to support the scaling of its kidneyintelX.dkd test, including the successful transfer of laboratory operations to a new facility in New York which increases testing capacity by over 3.5x and is projected to save over $2.6 million on a net present value basis over five years. Additionally, the company has completed the submission for CE marking of kidneyintelX.dkd, a crucial step for its use in global pharma clinical trials and potential comme</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/renalytix-plc/news/holdings-in-company-942</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/holdings-in-company-942</guid>
<pubDate>Thu, 16 Apr 2026 17:04:00 GMT</pubDate>
<description>UBS Group AG has notified Renalytix PLC that its trading book holdings have fallen below the 5% reporting threshold, resulting in a 0.000000% holding of voting rights as of April 15, 2026. This marks a decrease from their previous notification where they held 6.997265% of voting rights. The notification, dated April 16, 2026, indicates that UBS's trading book holdings are now exempt from further reporting.
Disclaimer*</description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/renalytix-plc/news/half-year-report-797</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/half-year-report-797</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>Renalytix plc reported a revenue increase to $1.6 million for the six months ended December 31, 2025, up from $1.3 million in the prior year, alongside a reduction in underlying EBITDA loss due to cost management. The company expanded its reach by adding 58 new practice sites and integrating with five EHR systems, up from two, and initiated eight additional integrations expected to benefit approximately 10,000 patients. A $9.5 million over-subscribed placing was completed at a premium to the pri</description>
</item>
<item>
<title>Further CEO Share Purchase</title>
<link>https://6ix.com/company/renalytix-plc/news/further-ceo-share-purchase-1</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/further-ceo-share-purchase-1</guid>
<pubDate>Fri, 13 Feb 2026 14:30:00 GMT</pubDate>
<description>Renalytix plc announced that its Chief Executive Officer, James McCullough, purchased an additional 750 American Depositary Shares (ADS) on February 12, 2026, at an average price of $3.15 per ADS, for a total transaction value of $2,362.50. Following this purchase, Mr. McCullough now holds an interest in 3,430,096 ordinary shares, representing 0.78% of the company's issued share capital. This transaction indicates continued confidence from the CEO in the company's prospects.
Disc</description>
</item>
<item>
<title>Director/PDMR Share Purchase</title>
<link>https://6ix.com/company/renalytix-plc/news/directorpdmr-share-purchase-9</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/directorpdmr-share-purchase-9</guid>
<pubDate>Thu, 12 Feb 2026 07:01:00 GMT</pubDate>
<description>Renalytix plc announced that Joel Jung, interim Chief Financial Officer, purchased 2,000 American Depositary Shares (ADS) at $2.90 per ADS on February 11, 2026, for a total transaction value of $5,800. Following this purchase, Mr. Jung holds an interest in 308,855 Ordinary Shares, representing 0.07% of the company's issued share capital. This transaction indicates insider confidence in the company's performance and prospects.
Disclaimer*</description>
</item>
<item>
<title>H1 Trading update</title>
<link>https://6ix.com/company/renalytix-plc/news/h1-trading-update-14</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/h1-trading-update-14</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Renalytix plc reported unaudited revenues of $1.6 million for the first half of fiscal year 2026, with full-year revenue guidance now projected at approximately $4 million, representing a 33% year-over-year increase. The company successfully implemented three new electronic medical record integrations in the first half, with more expected in the second half, and is planning a large-scale hospital group integration involving a 1,000-patient pilot. Renalytix is also advancing a real-world evidence</description>
</item>
<item>
<title>Three kidneyintelX.dkd Clinical Integrations</title>
<link>https://6ix.com/company/renalytix-plc/news/three-kidneyintelxdkd-clinical-integrations</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/three-kidneyintelxdkd-clinical-integrations</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the c</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/renalytix-plc/news/result-of-agm-1230</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/result-of-agm-1230</guid>
<pubDate>Tue, 09 Dec 2025 10:57:00 GMT</pubDate>
<description>Renalytix plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the adoption of the UK 2025 Annual Report (99.7% for) and the approval of the Directors' Remuneration Report (98.9% for). The re-appointment of directors received varying levels of support, with Christopher Mills at 90.3% and Erik Lium at 89.9% for, while other directors saw over 98% approval. The re-appointment of auditors PKF Littlejohn LLP was approved by 99.3% of votes, and the aut</description>
</item>
<item>
<title>Plan to Implement ADS Ratio Change</title>
<link>https://6ix.com/company/renalytix-plc/news/plan-to-implement-ads-ratio-change</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/plan-to-implement-ads-ratio-change</guid>
<pubDate>Tue, 25 Nov 2025 07:00:00 GMT</pubDate>
<description>Renalytix plc announced a plan to change its American Depository Share (ADS) ratio from one ADS representing two ordinary shares to one ADS representing fifty ordinary shares, effective around December 12, 2025. This change, equivalent to a one-for-twenty-five reverse ADS split, aims to improve ADS liquidity, reduce program costs, and potentially assist in meeting minimum bid price requirements for U.S. listing exchanges. While the proportional equity interest of ADS holders will remain unchange</description>
</item>
<item>
<title>Pivotal kidneyintelX.dkd data published</title>
<link>https://6ix.com/company/renalytix-plc/news/pivotal-kidneyintelxdkd-data-published</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/pivotal-kidneyintelxdkd-data-published</guid>
<pubDate>Wed, 12 Nov 2025 07:00:00 GMT</pubDate>
<description>Renalytix plc announced significant findings regarding its kidneyintelX.dkd test, with a manuscript published in Diabetes Care demonstrating improved risk classification for chronic kidney disease patients and showing that treatment with SGLT2i therapy in moderate to high-risk patients identified by the test resulted in a significant risk reduction. Additionally, three abstracts presented at ASN Kidney Week highlighted the successful implementation of kidneyintelX.dkd in a large health system, i</description>
</item>
<item>
<title>Publication of Annual Report & Notice of AGM</title>
<link>https://6ix.com/company/renalytix-plc/news/publication-of-annual-report-and-notice-of-agm-68</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/publication-of-annual-report-and-notice-of-agm-68</guid>
<pubDate>Tue, 04 Nov 2025 18:05:00 GMT</pubDate>
<description>Publication of Annual Report & Notice of AGM.</description>
</item>
<item>
<title>Audited Full Year Fiscal 2025 Results</title>
<link>https://6ix.com/company/renalytix-plc/news/audited-full-year-fiscal-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/audited-full-year-fiscal-2025-results</guid>
<pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
<description>Renalytix plc reported its audited fiscal year 2025 results, with total revenues up 30% to $3.0 million from $2.3 million in FY24. Testing revenue increased to $2.7 million, while pharmaceutical revenues grew by 200% to $0.3 million. The gross margin for the year was 40%, a significant increase from 9% in FY24. Administrative expenses totaled $18.4 million, down from $30.7 million. The company recognized $1.4 million in R&D tax credits. A loss of $0.6 million was recorded to adjust the VericiDx </description>
</item>
<item>
<title>Confirmation of receipt of £860k R&D tax credits</title>
<link>https://6ix.com/company/renalytix-plc/news/confirmation-of-receipt-of-pound860k-randd-tax-credits</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/confirmation-of-receipt-of-pound860k-randd-tax-credits</guid>
<pubDate>Mon, 27 Oct 2025 07:00:00 GMT</pubDate>
<description>Renalytix plc confirmed the receipt of £860k in Research and Development Tax Credits related to work completed in the fiscal years ending June 30, 2023, and June 30, 2024. The company received £296k during Q1 FY26, adding to the £564k received in Q4 FY25. Renalytix anticipates receiving an additional credit in early Q3 FY26 for work completed in FY25.
Disclaimer*</description>
</item>
<item>
<title>$4m balance sheet improvement with bond conversion</title>
<link>https://6ix.com/company/renalytix-plc/news/dollar4m-balance-sheet-improvement-with-bond-conversion</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/dollar4m-balance-sheet-improvement-with-bond-conversion</guid>
<pubDate>Fri, 10 Oct 2025 06:00:00 GMT</pubDate>
<description>Renalytix plc announced a $4 million balance sheet improvement due to the conversion of approximately $4 million of non-amortizing senior convertible bonds. This conversion involves the issuance of 31,650,034 ordinary shares to the Convertible Bond Investor at 9.5 pence per share. The conversion is expected to save up to $1.4 million in accrued interest over the loan's remaining life and improve the company's debt-to-equity ratio. Following admission, the company's total issued share capital wil</description>
</item>
<item>
<title>CE Mark application submission</title>
<link>https://6ix.com/company/renalytix-plc/news/ce-mark-application-submission</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/ce-mark-application-submission</guid>
<pubDate>Wed, 01 Oct 2025 06:00:00 GMT</pubDate>
<description>Renalytix has submitted an application for CE Mark certification in the European Union for its kidneyintelX.dkd test, aiming to enable clinical use across the EU. This action follows strategic partner interest, including discussions with a top 10 global pharmaceutical company regarding a global clinical trial. The company anticipates potential commercial opportunities, such as international distribution partnerships, in FY26 and/or FY27, upon successful CE mark achievement, expected in H1 2026. </description>
</item>
<item>
<title>£7.05m total gross proceeds from Fundraise</title>
<link>https://6ix.com/company/renalytix-plc/news/pound705m-total-gross-proceeds-from-fundraise</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/pound705m-total-gross-proceeds-from-fundraise</guid>
<pubDate>Fri, 26 Sep 2025 06:00:00 GMT</pubDate>
<description>Renalytix PLC announced the successful completion of its fundraise, generating total gross proceeds of approximately £7.05 million, equivalent to $9.5 million. This was achieved through an oversubscribed WRAP Retail Offer, which raised approximately £0.8 million via the issue of 8,421,052 new Ordinary Shares at a price of 9.5 pence per share. This was combined with the previously announced oversubscribed Placing, Subscription, and Additional Subscription, which involved the Placing and Subscript</description>
</item>
<item>
<title>Update Regarding Forward Guidance</title>
<link>https://6ix.com/company/renalytix-plc/news/update-regarding-forward-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/update-regarding-forward-guidance</guid>
<pubDate>Wed, 24 Sep 2025 13:00:00 GMT</pubDate>
<description>Renalytix plc clarified its forward revenue guidance, stating that it does not fully incorporate the potential impact of its recent collaboration with Tempus AI, Inc. Due to the early stage of the collaboration, the company is unable to predict the revenue contributions from this relationship. The company intends to provide shareholders with updates on the Tempus collaboration in the future. The kidneyintelX.dkd test has full reimbursement established by Medicare at $950 per reportable result.
</description>
</item>
<item>
<title>Investor Presentation and Revised Revenue Guidance</title>
<link>https://6ix.com/company/renalytix-plc/news/investor-presentation-and-revised-revenue-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/investor-presentation-and-revised-revenue-guidance</guid>
<pubDate>Tue, 23 Sep 2025 06:00:00 GMT</pubDate>
<description>Renalytix plc has released revised forward revenue guidance, anticipating $8.4 million in FY26. The company projects revenue of $19.0 million in FY27 and $42.0 million in FY28, reflecting the expected positive impact from their collaboration with Tempus AI, Inc. This updates the previous outlook provided in the Half Year Report on March 18, 2025, which estimated $8.5 million for FY26 and $17.5 million for FY27. The Board is evaluating the long-term benefits of the Tempus collaboration and plans </description>
</item>
<item>
<title>Result of Fundraise</title>
<link>https://6ix.com/company/renalytix-plc/news/result-of-fundraise-11</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/result-of-fundraise-11</guid>
<pubDate>Mon, 22 Sep 2025 16:30:00 GMT</pubDate>
<description>Renalytix plc successfully raised gross proceeds of £5.20 million through a placing and subscription of 54,741,582 new Ordinary Shares at a price of 9.5 pence per share. The placing was significantly oversubscribed. Four company directors subscribed for an aggregate of 2,815,789 shares, amounting to approximately £267,500. Application has been made for admission to the London Stock Exchange, with settlement of 9,253,679 First Tranche Placing Shares expected around September 26, 2025, and settlem</description>
</item>
<item>
<title>Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease</title>
<link>https://6ix.com/company/renalytix-plc/news/renalytix-announces-collaboration-with-tempus-to-advance-intelligent-risk-assessment-in-diabetic-kidney-disease</link>
<guid isPermaLink="true">https://6ix.com/company/renalytix-plc/news/renalytix-announces-collaboration-with-tempus-to-advance-intelligent-risk-assessment-in-diabetic-kidney-disease</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.</description>
</item>
</channel>
</rss>